| |
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
Today’s Big NewsOct 10, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab. Learn more about Foresight CLARITY™️. 
|
|
| By Zoey Becker After initially supporting a meeting with activist investor Starboard Value, Pfizer's former CEO and CFO publicly changed their tune after being threatened with litigation by Pfizer, Starboard alleges. |
|
|
|
By James Waldron Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has decided that all roads now lead to bankruptcy. |
By Fraiser Kansteiner In a letter to the chair of the U.S. Federal Trade Commission, Lina Khan, Sen. Elizabeth Warren is calling on the antitrust agency to “carefully scrutinize” Novo Holding’s multibillion-dollar bid for CDMO Catalent. |
By James Waldron Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted protein degraders. |
|
Wednesday, October 16, 2024 | 2pm ET / 11am PT Join experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques. 
|
|
By Fraiser Kansteiner B. Braun—one of the top IV solutions makers in the U.S.—has pledged to step up production in light of Baxter International's recent plant closure in the aftermath of Hurricane Helene. Despite being in the path of Hurricane Milton, a B. Braun plant in Florida has emerged largely unscathed. |
By Angus Liu In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. Now, with new data indicating the drug could prolong patients’ lives, the company is targeting an even wider label. |
By Conor Hale The company said that after a global search, it has appointed Mike Alvarez, former CEO of Qardio, to serve as its new chief. |
By Gabrielle Masson Syneos Health has tapped Costa Panagos to take the reins from former CEO Colin Shannon, who will transition to the role of executive chair. |
By Andrea Park With an FDA decision looming over its first foray into the acute pain space, Vertex Pharmaceuticals has commissioned a pair of surveys to take stock of that space. |
By Nick Paul Taylor Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing to pay LigaChem Biosciences up to $700 million for a potential first-in-class solid tumor candidate LCB97. |
By Darren Incorvaia To find RNA viruses hiding in genomic “dark matter,” researchers took advantage of one thing they all have in common: the RNA polymerase enzyme. |
By Conor Hale The company’s nine-figure series D follows up on the $84 million financing round it collected less than one year ago. |
By Nick Paul Taylor Zevra Therapeutics has partnered with the National Urea Cycle Disorders Foundation to run an awareness campaign designed to improve the diagnosis of conditions treated by one of its products. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now. 
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
